Toru Nishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Toru Nishi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Gunter A. Hofmann
Department of Neurosurgery, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto, 860-8556, Japan; ‡Shionogi Institute for Medical Science, 2-5-1 Mishima, Settsu, Osaka, 566-0022, Japan; and §Genetronics, Inc., 11199 Sorrento Valley Road, San Diego, CA 92121
1 shared publicationHideo Takeshima
Department of Neurosurgery, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto, 860-8556, Japan; ‡Shionogi Institute for Medical Science, 2-5-1 Mishima, Settsu, Osaka, 566-0022, Japan; and §Genetronics, Inc., 11199 Sorrento Valley Road, San Diego, CA 92121
1 shared publicationJun-Ichi Kuratsu
Department of Neurosurgery, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto, 860-8556, Japan; ‡Shionogi Institute for Medical Science, 2-5-1 Mishima, Settsu, Osaka, 566-0022, Japan; and §Genetronics, Inc., 11199 Sorrento Valley Road, San Diego, CA 92121
1 shared publicationKimio Yoshizato
Department of Neurosurgery, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto, 860-8556, Japan; ‡Shionogi Institute for Medical Science, 2-5-1 Mishima, Settsu, Osaka, 566-0022, Japan; and §Genetronics, Inc., 11199 Sorrento Valley Road, San Diego, CA 92121
1 shared publicationMasato Kochi
Department of Neurosurgery, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto, 860-8556, Japan; ‡Shionogi Institute for Medical Science, 2-5-1 Mishima, Settsu, Osaka, 566-0022, Japan; and §Genetronics, Inc., 11199 Sorrento Valley Road, San Diego, CA 92121
1 shared publicationSukhendu B. Dev
Department of Neurosurgery, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto, 860-8556, Japan; ‡Shionogi Institute for Medical Science, 2-5-1 Mishima, Settsu, Osaka, 566-0022, Japan; and §Genetronics, Inc., 11199 Sorrento Valley Road, San Diego, CA 92121
1 shared publication
Latest Publications
- 4 January 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (1) , 354-359
Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene
We report successful electro-gene therapy (EGT) by using plasmid DNA for tumor-bearing mice. Subcutaneously inoculated CT26 tumor was subjected to EGT, which consists of intratumoral injection of a naked plasmid encoding a marker gene or a therapeutic gene, followed by in vivo electroporation (EP). When this treatment modality is carried out with the plasmid DNA for the green fluorescent protein gene, followed by in vivo EP with the optimized pulse parameters, numerous intensely bright green fluorescent signals appeared within the tumor. EGT, by using the “A” fragment of the diphtheria toxin gene significantly inhibited the growth of tumors, by about 30%, on the flank of mice. With the herpes simplex virus thymidine kinase gene, followed by systemic injection of ganciclovir, EGT was far more effective in retarding tumor growth, varying between 50% and 90%, compared with the other controls. Based on these results, it appears that EGT can be used successfully for treating murine solid tumors.
- 4 January 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (1) , 354-359
Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene
We report successful electro-gene therapy (EGT) by using plasmid DNA for tumor-bearing mice. Subcutaneously inoculated CT26 tumor was subjected to EGT, which consists of intratumoral injection of a naked plasmid encoding a marker gene or a therapeutic gene, followed by in vivo electroporation (EP). When this treatment modality is carried out with the plasmid DNA for the green fluorescent protein gene, followed by in vivo EP with the optimized pulse parameters, numerous intensely bright green fluorescent signals appeared within the tumor. EGT, by using the “A” fragment of the diphtheria toxin gene significantly inhibited the growth of tumors, by about 30%, on the flank of mice. With the herpes simplex virus thymidine kinase gene, followed by systemic injection of ganciclovir, EGT was far more effective in retarding tumor growth, varying between 50% and 90%, compared with the other controls. Based on these results, it appears that EGT can be used successfully for treating murine solid tumors.